Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Sep;122(3):641-57.
doi: 10.1097/AOG.0b013e3182a1060e.

Antiphospholipid antibodies in stillbirth

Robert M Silver  1 , Corette B Parker, Uma M Reddy, Robert Goldenberg, Donald Coustan, Donald J Dudley, George R Saade, Barbara Stoll, Matthew A Koch, Deborah Conway, Radek Bukowski, Carol J Rowland Hogue, Halit Pinar, Janet Moore, Marian Willinger, D Ware Branch
Affiliations
Comparative Study

Antiphospholipid antibodies in stillbirth

Robert M Silver et al. Obstet Gynecol. 2013 Sep.

Abstract

Objective: To compare antiphospholipid antibodies in deliveries with and without stillbirth using a multicenter, population-based case-control study of stillbirths and live births.

Methods: Maternal sera were assayed for immunoglobulin (Ig)G and IgM anticardiolipin and anti-β2-glycoprotein-I antibodies. Assays were performed in 582 stillbirth deliveries and 1,547 live birth deliveries.

Results: Elevated levels of IgG anticardiolipin and IgG anti-β2-glycoprotein-I antibodies were associated with an approximate threefold increased odds of stillbirth (crude odds ratio [OR] 3.43, 95% confidence interval [CI] 1.79-6.60, 3.8% compared with 1.1% and OR 3.17, 95% CI 1.30-7.72, (1.9% compared with 0.6%, respectively) when all deliveries with stillbirth were compared with all deliveries with live birth. When the subset of stillbirths not associated with fetal anomalies or obstetric complications was compared with term live births, elevated IgG anticardiolipin antibodies were associated with stillbirth (5.0% compared with 1.0%; OR 5.30, 95% CI, 2.39-11.76; IgG anti-β2-glycoprotein-I antibodies (1.9% compared with 0.6%) had an OR of 3.00 (95% CI 1.01-8.90) and IgM anticardiolipin antibodies (6.0% compared with 3.0%) had an OR of 2.03 (95% CI 1.09-3.76). Elevated levels of anticardiolipin and anti-β2-glycoprotein-I antibodies were associated with a threefold to fivefold increased odds of stillbirth.

Conclusions: Our data support consideration of testing for antiphospholipid antibodies in cases of otherwise unexplained stillbirth.

Level of evidence: II.

PubMed Disclaimer

Conflict of interest statement

Financial Disclosure: The authors did not report any potential conflicts of interest.

Figures

Figure 1
Figure 1
Study enrollment and inclusion in antiphospholipid antibody analysis for A. stillbirth deliveries, B. live birth deliveries. A pregnancy was categorized as a stillbirth pregnancy if there were any stillbirths delivered and as a live birth pregnancy if all live births were delivered. A fetal death was defined by Apgar scores of 0 at 1 and 5 minutes and no signs of life by direct observation. Fetal deaths were classified as stillbirths if the best clinical estimate of gestational age at death was 20 weeks or more. Fetal deaths at 18 weeks and 19 weeks without good dating were also included as stillbirths. The analysis includes comparison of all stillbirths to all live births, all stillbirths to term live births, nonanomalous stillbirths to term live births, and nonanomalous stillbirths without obstetric complications to term live births.
See this image and copyright information in PMC

Comment in

  • Antiphospholipid antibodies in stillbirth.
    Peaceman AM. Peaceman AM. Obstet Gynecol. 2014 Jan;123(1):184. doi: 10.1097/AOG.0000000000000071. Obstet Gynecol. 2014. PMID: 24463684 No abstract available.
  • In reply.
    Branch DW, Parker CB. Branch DW, et al. Obstet Gynecol. 2014 Jan;123(1):184-185. doi: 10.1097/AOG.0000000000000070. Obstet Gynecol. 2014. PMID: 24463685 No abstract available.

References

    1. ACOG Practice Bulletin No. 118: Antiphospholipid Syndrome. Obstet Gynecol. 2011;117:192–199. - PubMed
    1. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80:614–620. - PubMed
    1. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14:131–134. - PubMed
    1. Miyakis S, Lockshin MD, Atsumi D, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J Thromb Haemost. 2006;4:295–306. - PubMed
    1. Meroni PL, Tedesco F, Locati M, et al. Antiphospholipid antibody mediated fetal loss: still an open question from a pathogenic point of view. Lupus. 2010;19:453–456. - PubMed

Publication types

Substances